三单倍型决定CYP2D6*2与*41的功能差异
该研究探究CYP2D6*2(功能正常)与*41(功能减低)差异的遗传基础。白种人队列基因分型未证实rs5758550对代谢比或肝表达的影响;细胞表达实验显示g.2989G>A是*41功能减低的因果变异,需以三单倍型解释*2与*41的功能差异。
要点
- g.2989G>A是CYP2D6*41功能减低的因果变异,与错误剪接增加相关。
- g.2851C>T单独降低酶活性与蛋白水平约50-65%,但可被g.4181G>C补偿。
- CYP2D6*2与*41的功能差异需以三单倍型组合解释,影响基因分型策略。
核心结论
- g.2989G>A是CYP2D6*41功能减低的因果变异。
- 需考虑三单倍型解释CYP2D6*2与*41的功能差异。
研究设计与样本
- 对两个白种人队列进行rs5758550A/G基因分型并分析其与CYP2D6*2的连锁及对代谢比或肝表达的影响。
- 在COS1与Huh7细胞中表达携带各变异或组合的基因组质粒以比较酶活性与蛋白水平。
主要发现
- 两个白种人队列证实rs5758550G与CYP2D6*2强连锁,但未发现其对sparteine代谢比或肝表达的影响。
- 与参考等位基因*1相比,g.2851C>T(R296C)和g.2989G>A均使酶活性与蛋白水平降低约50-65%,双变异仅约20%活性。
- g.2851C>T所致功能丧失可被g.4181G>C补偿(模拟*2的EM表型),但三变异中g.2989G>A的额外功能丧失未被补偿(模拟*41的IM表型)。
- 携带g.2989G>A者错误剪接增加,而携带g.2851C>T者未增加。
临床怎么用
- CYP2D6基因分型策略应纳入g.2989G>A并考虑三单倍型组合以区分*2与*41。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CYP2D6 metabolizes 20-25% of all clinically used drugs and its complex genetic polymorphism is a major determinant of drug safety and efficacy. We investigated the basis for the functional difference between the two common alleles *2 (g.2851C>T + g.4181G>C, normal function) and *41 (additional intronic g.2989G>A, reduced function). A recently reported far-distant enhancer polymorphism rs5758550A/G linked to *2 has been suggested to play a decisive role. Genotyping of two white cohorts confirmed strong linkage of rs5758550G to *2, whereas no influence was found on metabolic ratio of sparteine or hepatic expression. Genomic plasmid constructs carrying individual variants or combinations thereof were expressed in COS1 and Huh7 cells. Both g.2851C>T(R296C) and g.2989G>A reduced enzyme activity and protein levels similarly by ~ 50-65% compared to reference (*1), whereas the double variant had only ~ 20% activity. Although the unexpected loss of function caused by g.2851C>T was compensated by g.4181G>C (mimicking the EM-phenotype of *2), the additional loss of function due to intronic g.2989G>A in the triple variant was not compensated (mimicking the IM-phenotype of *41). We also confirmed increased erroneous splicing in carriers of g.2989G>A but not of g.2851C>T as a likely explanation for the impaired function of *41. In conclusion, our data demonstrate g.2989G>A as causal variant of impaired allele CYP2D6*41 whereas triple-haplotypes have to be considered to explain the functional difference between *2 and *41. These data are important for genotyping strategies and clinical implementation of CYP2D6 pharmacogenetics.
引用
- Zanger UM, Momoi K, Hofmann U, et al. Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41. Clin Pharmacol Ther. 2020. PMID: 33043448. doi:10.1002/cpt.2078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。